INTRODUCTION
MicroRNAs (miRNAs) are known as a new class of highly conserved 19-25 nucleotides non-protein-encoding RNAs in both plant and animal genomes and take crucial roles in a variety of biologic processes. 1, 2 MiRNAs genes are transcribed in a primary miRNA transcript by the RNA polymerase II enzyme, spliced, capped and polyadenylated. 3, 4 Therefore, by the RNase III endonuclease Drosha, primary miRNAs are processed into a stem-loop precursor termed pre-miRNA, 5 which are further cut into small RNA duplexes by Dicer RNase III endonuclease after transported to the cytoplasm by Exportin-5. [6] [7] [8] The functional strand of the miRNA duplex regulates the gene expression by binding to the 3 0 -untranslated regions (3 0 -UTR) of specific miRNAs, which are complementary or partially complementary recognition sequences of miRNAs, causing either degradation or translational inhibition. 9 This pre-translational level of governance is estimated to affect up to one-third of all human transcripts, including those involved in cancers. 10, 11 To date, 4700 miRNAs have been identified in human, and most of them are located within introns of protein-coding genes or within either introns or exons of non-coding transcriptional units. 12 MiRNAs are involved in a variety of important biologic processes, including cell death, proliferation, differentiation, stress resistance and fat metabolism. 9 Furthermore, recent evidences have shown that the dysregulation of miRNAs has been linked to cancer initiation and progression, indicating that miRNAs may act as either potent oncogenes or tumor-suppressor genes. 13 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), which is a type II membrane protein belonging to the TNF superfamily, is initially identified by homology to the C-terminal extracellular domain of other TNF family members such as Fas ligand, TNF-a and lymphotoxin a.
14 Various evidences have shown that TRAIL can induce apoptosis only in tumor cells but not normal cells. 15 There are four distinct membrane-bound TRAIL receptors, 16 and only death receptor 4 (DR4, TRAIL-R1) and death receptor 5 (DR5, TRAIL-R2) are capable of signaling apoptosis. 17, 18 DR4 and DR5 contain a functional cytoplasmic death domain and are able to deliver the apoptosis signal of TRAIL by association with the deathinducing signaling complex, which contains the Fas-associated death domain protein, procaspase-8 and cellular FLICE-inhibitory protein. 18, 19 Procaspase-8 can be autocatalytically cleaved or activated at the death-inducing signaling complex, and then in turn activate downstream effector caspases, caspase-3 and -7 with an irreversible ensuring commitment to apoptosis. 20 The other two receptors, TRAIL-neutralizing decoy receptors 1 and 2 (DcR1 and DcR2), are recognized as 'decay receptors', which lack a functional death domain and cannot interact with Fas-associated death domain protein or induce apoptosis. But they can also block the TRAIL pathway by competing ligand, which bind to DR4 and DR5. 21 The TRAIL pathway is found to have important roles in host antitumor and anti-metastasis defense.
As the importance of the TRAIL pathway in cancers, many current researches focus on the use of TRAIL in cancer treatment. Several different drugs targeting TRAIL receptors have been developed and are being tested in human clinical trials. 22 However, a significant proportion of human cancer cells are resistant to TRAIL-induced apoptosis, which may limit the clinical effectiveness of these agents. For example, it has been reported that primary astrocytoma cells and B-cell chronic lymphocytic leukemia cells are resistant to TRAIL. 22 In addition, up to half of tumor cell lines may be TRAIL resistant. To date, many current researches find that miRNAs are involved in TRAIL-induced apoptosis, indicating miRNAs may be a promising molecular target to reverse TRAIL resistance.
This article reviews the current findings about miRNAs involved in the apoptosis process of TRAIL pathway in different cancers (Table 1) .
HUMAN NON-SMALL CELL LUNG CANCER
Lung cancer is the most common cause of cancer-related deaths worldwide and non-small cell lung cancer (NSCLC) accounts for approximately 80% of all cases of lung cancer. Only 20-30% of standard treatments for NSCLC have a positive clinical response. Although TRAIL has been known to induce apoptosis in a variety of different tumor types, but many tumors, including NSCLC, are resistant to TRAIL, which limits the clinical application of TRAIL. 23, 24 To investigate miRNAs involved in TRAIL resistance, Garofalo et al. 25 analyzed miRNAs expression profile in TRAIL-resistant (CALU-1) and semi-resistant NSCLC cell lines (A459 and A549) vs a TRAIL-sensitive cell line (H460). The results showed that levels of different miRNAs, particularly miR-221 and miR-222, were increased in TRAIL-resistant NSCLC cells. Furthermore, they proved that H460 TRAIL-sensitive cells transfected with pre-miR-221 and miR-222 became resistant to TRAIL, whereas CALU-1 TRAIL-resistant cells transfected with anti-miR-221 and miR-222 became sensitive to TRAIL, indicating high expression levels of miR-221 and miR-222 are needed to maintain the TRAIL-resistant phenotype.
Further studies have demonstrated that miR-221 and miR-222 induce TRAIL resistance by directly targeting 3 0 -UTRs of phosphatase and tensin homolog, tissue inhibitor of metalloproteinase-3 (TIMP3) and the cyclin-dependent kinase inhibitor p27kip1. [26] [27] [28] [29] [30] Downregulation of phosphatase and tensin homolog deleted on chromosome 10, TIMP3 and p27kip1 small interfering RNA can render TRAIL-sensitive NSCLC cells resistant to TRAIL, which indicates that miR-221 and miR-222 modulated TRAIL sensitivity in NSCLC cells mainly through phosphatase and tensin homolog deleted on chromosome 10, TIMP3 and p27kip1.
Acunzo et al. 31 performed further research and demonstrated that miR-130a was expressed at low level in NSCLC cell lines, and miR-130a was able to reduce TRAIL resistance in NSCLC cells through the downregulation of miR-221 and miR-222 by targeting hepatocyte growth factor receptor (MET). After the introduction of miR-130a, A549 cells became more sensitive to TRAIL-induced cell death and the endogenous expression levels of miR-221 and miR-222 were decreased. MET receptor, a member of the tyrosine kinase receptor family, is normally expressed in cells of epithelial origin. 32 Hepatocyte growth factor/scatter factor is the ligand of MET. Activation of the MET receptor by its cognate ligand hepatocyte growth factor/scatter factor factor is able to counteract apoptosis and promotes survival of many cell types exposed to apoptosis inducers, including death receptor activation, serum starvation and genotoxic treatment. 33 Acunzo et al. 31 showed that enhanced expression of miR-130a strongly reduces MET endogenous protein in NSCLC cell lines including CALU-1, H1299, A459 and A459. Further investigation showed that MET regulated the expression of miR-221 and miR-222 through activator protein-1 and c-Jun N-terminal kinase, particularly c-Jun. 26 Taking together, miR-130a by targeting MET is able to induce TRAIL sensitivity in NSCLC cells through the activator protein-1 and c-Jun N-terminal kinase, which are mediated the downregulation of miR-221 and miR-222.
According to Incoronato et al., 34 miR-212 increased TRAIL sensitivity of NSCLC cells by targeting the anti-apoptotic protein PED/PEA-15 (phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes). 35, 36 PED/PEA-15, a death effector domain family member of 15 kDa, is an endogenous protein inhibiting FAS and TNFR1-mediated apoptosis. 37 In NSCLC, PED/PEA-15 is upregulated and induces resistance to TRAIL. 38 Incoronato et al. 34 first identified miR-212 as a negative regulator of PED/PEA-15 expression. They have found that PED/PEA-15 is upregulated and miR-212 is rarely expressed in NSCLC, and their expressions are inversely correlated. Ectopic expression of miR-212 increases TRAIL-induced cell death in NSCLC cells. In contrast, inhibition of endogenous miR-212 by antago-miR results in increase of PED/PEA-15 protein expression and resistance to TRAIL treatment.
LIVER CANCERS
Hepatocellular carcinoma (HCC) accounts for 80 to 90% of primary liver cancer. HCC is a primary malignancy of the hepatocyte, generally leading to death within 6-20 months. Cholangiocarcinoma (CCA) is a primary tumor arising from the bile duct epithelium and is the second most common primary hepatobiliary cancer after HCC. 39 It has been proved that many CCA and HCC cell lines are resistant to apoptosis mediated by TRAIL. 40 To date, several miRNAs relating to TRAIL resistance in HCC and CCA have been identified. 41 MiR-25 hosted by MCM7 gene is 22 nucleotides in length, and transcribed as part of the miR-106bB25 polycistron. The consistent overexpression of the miR-106bB25 cluster and its role in cell proliferation and anchorage-independent growth points to the oncogenic potential of this cluster. 42, 43 According to Razumilava et al., 44 increased host gene MCM7 expression could explain the elevation of miR-25 in CCA cells. Moreover, increased miR-25 protected, and conversely, decreased miR-25 could sensitize CCA cell lines to TRAIL-induced apoptosis, indicating 26 have demonstrated that miR-221 and miR-222 induce TRAIL resistance via targeting phosphatase and tensin homolog and TIMP3 tumor suppressors and MET oncogene is involved in miR-221 and miR-222 activation through the c-Jun not only in NSCLC cells but also in HCC cells.
GILOBLASTOMA
Malignant glioma (glioblastoma) is the most common malignant brain tumor, characterized by a rapid and devastating clinical course. Despite surgery and radiation with or without adjuvant chemotherapy, malignant glioma remains an almost uniformly fatal disease, 49, 50 underscoring the need for improved therapy. Recent researches have suggested that dysregulated miR-21 that can mediate anti-apoptosis effect may contribute to the malignant transformation of glioblastoma. Chan et al. 51 performed a miRNA-profiling screen and found that miR-21 was a candidate miRNA dysregulated in gliomas. Then they confirmed the overexpression of miR-21 by oligonucleotide array and northern blot analysis. As we know, propensity to proliferation and resistance to apoptosis are two fundamental characteristics of neoplastic cells. Downregulation of miR-21 in two glioblastoma cell lines dramatically reduced metabolic activity and increased spontaneous apoptosis of the two cultures, 52 which indicates that miR-21 is a novel therapeutic target in glioblastoma.
Transgenic neural precursor cells with the gene-encoding TRAIL has been proved effective in the treatment of glioblastoma. 53 As we know, the blood-brain barrier forms obstacles to conventional glioblastoma treatment, mandating therapeutic alternatives that provide specific local drug delivery. 54, 55 Neural precursor cell, as an endogenous or transplantable source of newly generated neural cells, may approach to local delivery. 53 Shah et al. 56, 57 have promoted an enhanced apoptosis-inducing secretable form of recombinant TRAIL (S-TRAIL) with longer biological half-life in glioma cells. Neural precursor cell-S-TRAIL could migrate into the tumors and selectively kill neoplastic cells. Further investigation by Maarten et al. 52 showed that the combined suppression of miR-21 and neural precursor cell-S-TRAIL led to a synergistic antitumor effect in the treatment of glioblastoma both in vitro and in vivo.
OTHERS
There are other miRNAs that are capable of regulating TRAILinduced apoptosis in breast cancer, ovarian cancer and pediatric renal cancer.
Dmitriy et al. 58 uncovered several miRNAs involved in the regulation of TRAIL-induced apoptosis signaling in MDA-MB-453 breast cancer cell line. They found that miR-145, miR-216, miR-182 and miR-96 could interact with DR4/5 and Fas-associated death domain protein. Overexpression of these miRNAs reduced caspase-3 activation through TRAIL-induced apoptosis signaling.
The Six1 homeoprotein, a member of the homeobox gene family, has been demonstrated to have an important role in both normal development [59] [60] [61] [62] and tumorigenesis, 63, 64 but relatively little known about its dysregulation, particularly in cancers. Recent research by Imam et al. 65 found decreased miR-185 expression, paralleling an increase in Six1 levels, by analyzing the expression of Six1 and miR-185 in ovarian cancers, pediatric renal tumors and multiple breast cancer cell lines. Further experiments have revealed that miR-185 represses Six1 by binding to its 3 0 -UTR and mediates its tumor-suppressor function partially by regulating Six1 transcriptional targets c-myc and cyclin A1. However, Six1 has been shown as a suppressor of the TRAIL-mediated apoptosis by earlier research. 66 More importantly, miR-185 can sensitize Six1-overexpressing resistant cancer cells to TRAIL-mediated apoptosis. 65 It is worth mentioning that miR-185-Six1 signaling pathway may not be the only pathway in TRAIL regulation. 65 All data suggest that the altered expression of miR-185, a novel tumor suppressor, may be one of the central events leading to dysregulation of oncogenic protein Six1 in human cancers.
Bladder cancer is the most common type of urologic cancer in Chinese males. With northern blot analysis, Lu et al. 67 found miR-221 significantly upregulated in TRAIL-resistant T24 and TRAILsensitive RT4 bladder cancer cells compared with normal human urothelial cells, whereas the expression level of miR-221 in T24 cells was higher than in RT4 cells. Antagonism of miR-221 could upregulate the apoptosis rates in T24 cells, by an up-modulation of p27kip1 and active form of caspase-3, which indicates that miR-221 silencing is able to change the resistant TRAIL phenotype to a sensitive one. Similar results have been reported in other neoplastic cell lines by Garofalo et al. 25 Prostate cancer, approximately 29% of cancer incidence, is the second only to lung cancer in male cancer death in the United States. MiR-145, which has been shown to act as a tumor suppressor in breast and colon cancers, was found to be consistent downregulated in prostate tumors. The upregulation of pro-apoptotic genes TNFSF10 (a TRAIL ligand that belongs to the TNF family) can be detected in miR-145-overexpressing prostate cancer cells, which indicates that miR-145 may regulate TRAIL-induced apoptosis. 68, 69 What's more, a few days ago, Juan et al. 70 revealed that rendered resistant HeLa cells transfected with miR-133b were sensitive to TRAIL-induced apoptosis. In addition, comparing with matching healthy tissue, expression of miR-133b was significantly downregulated in 75% of the prostate cancer cases.
CONCLUSIONS TRAIL receptors are attractive therapeutic targets in cancer, which can induce tumor cell apoptosis and have minimal toxicity to normal tissues. There are already a large number of different TRAIL receptor agonists, which are being tested in human clinical trials. 71 Recently, many researches have been done to investigate the mechanism of resistance to TRAIL, and several mechanisms have been proposed. 24 The restricted expression of the different TRAIL receptors can regulate the induction of TRAIL-induced apoptosis. Another option for explaining the resistance of TRAIL-induced apoptosis relates to cell cycle progression. In addition, high level of XIAP expression has been demonstrated that it may lead to TRAIL resistance by directly inhibiting caspases 3, 7 and 9. However, the mechanism of TRAIL-induced apoptosis is not very definite. MiRNAs that have been proved to be related to cancer initiation and progression, are involved in TRAIL-induced apoptosis, and may become a promising molecular target to reverse TRAIL resistance.
In conclusion, the common science discussed in this paper suggests that miRNAs take an important role in TRAIL-mediated apoptosis in different cancers. The TRAIL-mediated apoptosis pathway can be sensitive with some miRNAs, such as miR-29, miR130a, miR-212, and miR-185, whereas resistant with some other miRNAs, such as miR-25, miR-222 and miR-221. So miRNAs might be used as a biomarker to predict the response to chemotherapy with malignant tumors through the TRAIL pathway. In addition, miRNAs combined with TRAIL signal pathway might provide a novel strategy to treat malignant tumors in the future, in the meanwhile there is still much work to be done.
